Kevin Pong

Kevin Pong

Company: Anima Biotech

Job title: CBO


mRNA Lightning Platform – Discovery of Small Molecule mRNA Drugs & Their Mechanisms of Action 11:45 am

Target space opportunity: an overview of Anima’s mRNA biology modulators mRNA Lightning platform combines high scale phenotypic screening with MOAi technology using AI to elucidate the mechanism of action of active molecules Anima’s Lightning software oversees the whole discovery process, from hit generation to AI-driven MOA elucidationRead more

day: Day Two

Biopharma & Investment Partnerships Panel — Exploring the Future of RNA Investment & Collaborations Space for Small Molecules 11:30 am

The biopharmaceutical sector is considering small molecule medications as a vital component. This community thrives on strategic alliances, which allow for cross-functional sharing of knowledge, skills, and experience across different disciplines to truly advance RNA-targeted small molecule drugs to patients. This session is the ideal opportunity to get face-to-face time with many of the brightest…Read more

day: Day One

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.